Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276)
64.98
+0.99 (1.55%)
Aug 22, 2025, 3:00 PM CST
Jiangsu Hengrui Medicine Revenue
Jiangsu Hengrui Medicine had revenue of 8.56B CNY in the quarter ending June 30, 2025, with 12.53% growth. This brings the company's revenue in the last twelve months to 30.15B, up 19.38% year-over-year. In the year 2024, Jiangsu Hengrui Medicine had annual revenue of 27.98B with 22.63% growth.
Revenue (ttm)
30.15B
Revenue Growth
+19.38%
P/S Ratio
14.34
Revenue / Employee
1.49M
Employees
20,238
Market Cap
432.34B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.98B | 5.16B | 22.63% |
Dec 31, 2023 | 22.82B | 1.54B | 7.26% |
Dec 31, 2022 | 21.28B | -4.63B | -17.87% |
Dec 31, 2021 | 25.91B | -1.83B | -6.59% |
Dec 31, 2020 | 27.73B | 4.45B | 19.09% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Shenzhen Mindray Bio-Medical Electronics | 35.59B |
WuXi AppTec | 41.90B |
Sichuan Biokin Pharmaceutical | 441.19M |
Zhangzhou Pientzehuang Pharmaceutical., | 10.52B |
Aier Eye Hospital Group | 21.81B |
Shanghai United Imaging Healthcare | 10.43B |
Yunnan Baiyao Group Co.,Ltd | 40.10B |
Huadong Medicine | 42.62B |